<DOC>
	<DOCNO>NCT00382733</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness oral topotecan well chemotherapy tolerate ( side effect ) give different dose level . The study also collect information medication break absorbed body quality life affect treatment .</brief_summary>
	<brief_title>Oral Topotecan Treat Recurrent Persistent Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Topotecan</mesh_term>
	<criteria>Patient provide write informed consent prior studyspecific screening procedure , understand patient right withdraw study time , without prejudice . Male female patient . Patient least 18 year age recurrent persistent solid tumor . Patient adequate hematologic function ( absolute neutrophil count [ ANC ] &gt; = 1500/mL platelet &gt; = 100,000/mL ) , adequate renal function ( serum creatinine &lt; 2.0 mg/dL ; calculate creatinine clearance &gt; 40 mL/min ) , adequate hepatic function ( serum bilirubin &lt; = 1.5 mg/dL transaminase &lt; = 3 time upper limit normal [ 3 x ULN ] ) . Patient Eastern Oncology Cooperative Group ( ECOG ) performance status &lt; = 2 . Patient life expectancy least 3 month time enrollment . Patient medical problem , unrelated malignancy , sufficient severity would limit full compliance study would expose him/her undue risk . Patient receive 2 prior treatment regimens prior enrollment include chemotherapy , hormonal therapy , biologic therapy , immunotherapy . Patient negative serum urine pregnancy test within 7 day prior start therapy ( female childbearing potential ) . Patient pregnant lactate woman . Women childbearing potential either positive pregnant test ( serum urine ) baseline . Women childbearing potential use reliable appropriate contraceptive method exclude . ( Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . ) Patients must agree continue contraception 30 day date last study drug administration . Patient serious , uncontrolled , concurrent infection ( ) . Patient receive whole pelvic extend field radiation therapy within 4 week enrollment . Patients fully recover whose acute toxicity relate prior radiotherapy return baseline ineligible . Patient receive myelosuppressive chemotherapy within last 4 week recover myelosuppressive effect recent chemotherapy . Patient receive another investigational agent within 4 week prior study enrollment . Patient known hypersensitivity topoisomerase I inhibitor . Patient unable swallow capsule disease know affect drug absorption , short gut syndrome active radiation enteritis . Patient receive drug know alter absorption antacid , proton pump blocker ( eg , omeprazole ) , H2 receptor antagonist ( eg , cimetidine ) . A washout period one week ( 7 day ) require prior initiate study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Solid Tumors</keyword>
</DOC>